Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.
Psyence Group is one step closer to achieving British Standards Institute (BSI) certification , having completed its first official validated harvest of psychedelic mushrooms (psilocybe cubensis) at its federally-licensed facility In Lesotho, Southern Africa. The state-of-the-art facility has been built to GMP standards, is FDA registered and has been operational since January 2021.
Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.
Dr Amza Ali, neurologist and global medical director at Psyence shares some more light on this subject explaining what palliative care is, why it needs more attention and what Psyence’s vision and mission are when it comes to improving the access to and the effectiveness of palliative care globally.
This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.
Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.
We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.
We believe that natural psilocybin offers multiple benefits for the long-term treatment of mental health conditions that may result from trauma. Plant-based and natural remedies are our preferred route as conscious consumers increasingly seek more natural treatments when it comes to supporting their mental wellbeing.
It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.